ADHD medication use following FDA risk warnings
Colleen L Barry1, Andres Martin, Susan H Busch
1Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore MD, 21205, USA. cbarry@jhsph.edu
The Journal of Mental Health Policy and Economics
|September 25, 2012
Summary
FDA safety warnings for attention deficit/hyperactivity disorder (ADHD) medications did not significantly decrease pediatric use. Balanced news coverage likely influenced treatment patterns, contrasting with antidepressant warnings.
Area of Science:
- Pharmacovigilance and Public Health
- Pediatric Psychiatry
- Health Communication
Background:
- The U.S. Food and Drug Administration (FDA) issued safety warnings in 2006 regarding cardiac and psychiatric risks of ADHD medications.
- Concerns were raised about the potential impact of these warnings on pediatric ADHD treatment patterns.
Purpose of the Study:
- To evaluate the effect of ADHD medication safety risk disclosures on pediatric use.
- To analyze news media coverage of ADHD medication risks and benefits to understand treatment trends.
Main Methods:
- Utilized the Medical Expenditure Panel Survey (MEPS) to track pediatric ADHD medication use rates from 2002-2008.
- Conducted content analysis of news coverage across major U.S. media outlets, examining risk and benefit portrayals.
Main Results:
- No significant decline in pediatric ADHD medication use was observed following FDA safety warnings.
- News media coverage of ADHD medication risks and benefits was found to be relatively balanced.
Conclusions:
- ADHD medication safety warnings did not lead to substantial decreases in use, possibly due to balanced media reporting.
- Findings contrast with antidepressant warnings, where risk-focused media amplified usage declines.
- The study highlights the need for robust FDA post-marketing surveillance and further research into treatment changes post-warnings.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:30Attention-Deficit/Hyperactivity Disorder
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...